Unnati Pharmax

Gemtide 750 Teriparatide Injection IP
Composition: Teriparatide 750 µg/ml Injection
International Trade Name: Forsteo® / Teribone®

Gemtide 750 is a high-quality Teriparatide injection, a biosimilar equivalent of the internationally recognized parathyroid hormone (PTH 1-34) formulations marketed under the brand names Forsteo® and Teribone®. Manufactured in WHO-GMP certified facilities, Gemtide is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs for bone-related disorders.

Teriparatide is a recombinant form of human parathyroid hormone that stimulates new bone formation by activating osteoblast function. Gemtide 750 effectively increases bone mineral density and reduces the risk of fractures in patients with severe osteoporosis.

Gemtide 750 Teriparatide Injection IP is primarily indicated for the treatment of osteoporosis in postmenopausal women, treatment-induced osteoporosis in men and women, and patients at high risk of fractures who require anabolic therapy to strengthen bones.

Gemtide 750 Teriparatide Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Terlipressin Erliso Injection
Composition: Terlipressin 1mg / 2mL Solution for Injection
International Trade Name: Glypressin®

Terlipressin Erliso is a high-quality Terlipressin 1mg Injection, a synthetic vasopressin analog, widely recognized under the international brand name Glypressin®. Manufactured in WHO-GMP certified facilities, Erliso Injection is supplied by trusted pharmaceutical exporters from India to support advanced global critical care and hepatology treatment programs, particularly in patients with variceal bleeding, hepatorenal syndrome, and other circulatory complications.

Terlipressin is a vasopressin receptor agonist that induces vasoconstriction, reducing portal venous pressure and improving renal perfusion. Terlipressin Erliso Injection is primarily indicated for the management of acute variceal bleeding, hepatorenal syndrome in cirrhotic patients, and other conditions requiring vasopressor support.

Terlipressin Erliso Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, critical care units, and international pharmaceutical distributors.

Natzold Zoledronic Acid Injection
Composition: Zoledronic Acid 4mg / 5mL Solution for Injection
International Trade Name: Reclast® / Zometa®

Natzold is a high-quality Zoledronic Acid 4mg Injection, a bisphosphonate widely recognized under the international brand names Reclast® and Zometa®. Manufactured in WHO-GMP certified facilities, Natzold Injection is supplied by trusted pharmaceutical exporters from India to support advanced global osteoporosis, bone metastasis, and bone-related treatment programs, particularly in patients at risk of fractures or with malignant bone disease.

Zoledronic Acid is a potent bisphosphonate that inhibits osteoclast-mediated bone resorption, helping to increase bone mass and reduce the risk of fractures. Natzold 4mg Injection is primarily indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, prevention of skeletal-related events in patients with bone metastases, and management of hypercalcemia of malignancy.

Natzold Zoledronic Acid Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, oncology and osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Natzold Zoledronic Infusion 5 mg
Composition: Zoledronic Acid 5 mg/100 ml Infusion
International Trade Name: Zometa® / Reclast®

Natzold 5 mg is a high-quality Zoledronic Acid infusion, a bisphosphonate equivalent of the internationally recognized products Zometa® and Reclast®. Manufactured in WHO-GMP certified facilities, Natzold is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs for bone-related disorders and oncology care.

Zoledronic Acid is a potent bisphosphonate that inhibits osteoclast-mediated bone resorption, improving bone mineral density and reducing the risk of skeletal-related events. Natzold is used in the management of conditions such as osteoporosis, Paget’s disease of bone, hypercalcemia of malignancy, and prevention of skeletal complications in patients with bone metastases from solid tumors.

Natzold Zoledronic Infusion 5 mg is primarily indicated for the treatment and prevention of osteoporosis in postmenopausal women, management of hypercalcemia of malignancy, and prevention of skeletal-related complications in patients with metastatic bone disease.

Natzold 5 mg Infusion is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The infusion is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, oncology centers, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Zoldonat Zoledronic Acid Injection
Composition: Zoledronic Acid 4mg / 5mL Solution for Injection
International Trade Name: Reclast® / Zometa®

Zoldonat is a high-quality Zoledronic Acid 4mg Injection, a bisphosphonate widely recognized under the international brand names Reclast® and Zometa®. Manufactured in WHO-GMP certified facilities, Zoldonat Injection is supplied by trusted pharmaceutical exporters from India to support advanced global osteoporosis, bone metastasis, and bone-related treatment programs, particularly in patients at risk of fractures or with malignant bone disease.

Zoledronic Acid is a potent bisphosphonate that inhibits osteoclast-mediated bone resorption, helping to increase bone mass and reduce the risk of fractures. Zoldonat 4mg Injection is primarily indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, prevention of skeletal-related events in patients with bone metastases, and management of hypercalcemia of malignancy.

Zoldonat Zoledronic Acid Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, oncology and osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Olimab 60 Denosumab Solution
Composition: Denosumab 60 mg/ml Injection
International Trade Name: Prolia® / Xgeva®

Olimab 60 is a high-quality Denosumab injection solution, a biosimilar equivalent of the internationally recognized RANKL-targeting monoclonal antibody marketed under the brand names Prolia® and Xgeva®. Manufactured in WHO-GMP certified facilities, Olimab 60 is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs for bone-related disorders.

Denosumab is a fully human monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand), a key mediator of osteoclast formation, function, and survival. By blocking RANKL, Olimab 60 effectively reduces bone resorption and strengthens bone density, making it an essential therapy for conditions such as osteoporosis, bone loss associated with hormone ablation therapy in cancer patients, and prevention of skeletal-related events in patients with bone metastases.

Olimab 60 Denosumab Solution is primarily indicated for the treatment of osteoporosis in postmenopausal women, treatment-induced bone loss, and management of skeletal complications in patients with solid tumors or multiple myeloma.

Olimab 60 Denosumab Solution is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, oncology centers, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Bonmax PTP Teriparatide Injection IP
Composition: Teriparatide 20µg / 1mL Solution for Injection
International Trade Name: Forteo®

Bonmax PTP is a high-quality Teriparatide 20µg Injection, a recombinant human parathyroid hormone (1-34) analog, marketed under the internationally recognized brand name Forteo®. Manufactured in WHO-GMP certified facilities, Bonmax PTP Injection is supplied by trusted pharmaceutical exporters from India to support advanced global osteoporosis and bone health treatment programs, particularly in patients at high risk of fractures.

Teriparatide is a recombinant form of the biologically active fragment of human parathyroid hormone, which stimulates new bone formation by activating osteoblast function. Bonmax PTP Teriparatide Injection is primarily indicated for the treatment of severe osteoporosis in postmenopausal women and men at high risk of fracture, and in patients with glucocorticoid-induced osteoporosis.

Bonmax PTP Teriparatide Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

ZOLEJAS Zoledronic Acid Injection IP 4mg
Composition: Zoledronic Acid 4mg / 5mL Solution for Injection
International Trade Name: Reclast® / Zometa®

ZOLEJAS is a high-quality Zoledronic Acid 4mg Injection, a bisphosphonate widely recognized under the international brand names Reclast® and Zometa®. Manufactured in WHO-GMP certified facilities, ZOLEJAS Injection is supplied by trusted pharmaceutical exporters from India to support advanced global osteoporosis, bone metastasis, and bone-related treatment programs, particularly in patients at risk of fractures or with malignant bone disease.

Zoledronic Acid is a potent bisphosphonate that inhibits osteoclast-mediated bone resorption, helping to increase bone mass and reduce the risk of fractures. ZOLEJAS 4mg Injection is primarily indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, prevention of skeletal-related events in patients with bone metastases, and management of hypercalcemia of malignancy.

ZOLEJAS Zoledronic Acid Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, oncology and osteoporosis clinics, government health programs, and international pharmaceutical distributors.

RALOXIHEAL 60 mg Tablets
Composition: Raloxifene Hydrochloride 60 mg per tablet
International Trade Name: Evista®

RALOXIHEAL 60 mg is a high-quality Raloxifene Hydrochloride tablet, a selective estrogen receptor modulator (SERM) equivalent of the internationally recognized product Evista®. Manufactured in WHO-GMP certified facilities, RALOXIHEAL is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs for bone-related disorders.

Raloxifene Hydrochloride selectively binds to estrogen receptors, mimicking estrogen’s beneficial effects on bone and lipid metabolism while antagonizing estrogen activity in breast and uterine tissues. This helps in maintaining bone density, reducing the risk of fractures, and providing preventive benefits against certain estrogen-sensitive cancers.

RALOXIHEAL 60 mg Tablets are primarily indicated for the prevention and treatment of postmenopausal osteoporosis in women, as well as for reducing the risk of invasive breast cancer in postmenopausal women at high risk.

RALOXIHEAL 60 mg Tablets are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Zoltero 4 mg Injection
Composition: Zoledronic Acid 4 mg/5 ml Injection
International Trade Name: Reclast® / Zometa®

Zoltero 4 mg is a high-quality Zoledronic Acid injection, a bisphosphonate equivalent of the internationally recognized products Reclast® and Zometa®. Manufactured in WHO-GMP certified facilities, Zoltero is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs for bone-related disorders and oncology care.

Zoledronic Acid is a potent bisphosphonate that inhibits osteoclast-mediated bone resorption, improving bone mineral density and reducing the risk of skeletal-related events. Zoltero is used in the management of conditions such as osteoporosis, Paget’s disease of bone, hypercalcemia of malignancy, and prevention of skeletal complications in patients with bone metastases from solid tumors.

Zoltero 4 mg Injection is primarily indicated for the treatment and prevention of osteoporosis in postmenopausal women, management of hypercalcemia of malignancy, and prevention of skeletal-related complications in patients with metastatic bone disease.

Zoltero 4 mg Injection is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, oncology centers, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Esentra 120 Denosumab Solution for Injection
Composition: Denosumab 120mg / 1mL Solution for Injection
International Trade Name: Prolia®

Esentra 120 is a high-quality Denosumab 120mg Solution for Injection, a biosimilar equivalent of the internationally recognized RANKL-targeted monoclonal antibody marketed under the brand name Prolia®. Manufactured in WHO-GMP certified facilities, Esentra Injection is supplied by trusted pharmaceutical exporters from India to support advanced global osteoporosis and bone health treatment programs, particularly in patients at high risk of fractures.

Denosumab is a fully human monoclonal antibody that binds to and inhibits RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand), preventing osteoclast formation, function, and survival, thereby reducing bone resorption and increasing bone mass and strength. Esentra 120mg Solution for Injection is primarily indicated for the treatment of osteoporosis in postmenopausal women, men at increased risk of fractures, and patients receiving certain cancer therapies that compromise bone health.

Esentra 120 Denosumab Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Domvel 60 mg Pre-filled Syringe (PFS) Injection 1 ml
Composition: Denosumab 60 mg/ml Injection
International Trade Name: Prolia® / Xgeva®

Domvel 60 mg PFS is a high-quality Denosumab injection in a ready-to-use pre-filled syringe, a biosimilar equivalent of the internationally recognized RANKL-targeting monoclonal antibody marketed under the brand names Prolia® and Xgeva®. Manufactured in WHO-GMP certified facilities, Domvel is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs for bone-related disorders.

Denosumab is a fully human monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand), a key mediator of osteoclast formation, function, and survival. By blocking RANKL, Domvel effectively reduces bone resorption and strengthens bone density, making it an essential therapy for conditions such as osteoporosis, bone loss associated with hormone ablation therapy in cancer patients, and prevention of skeletal-related events in patients with bone metastases.

Domvel 60 mg PFS Injection is primarily indicated for the treatment of osteoporosis in postmenopausal women, treatment-induced bone loss, and management of skeletal complications in patients with solid tumors or multiple myeloma.

Domvel 60 mg PFS Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The pre-filled syringe is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, oncology centers, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

DENUB 60 mg Injection Twin Pack (2 PFS)
Composition: Denosumab 60 mg/ml Injection (r-DNA origin)
International Trade Name: Prolia® / Xgeva®

DENUB 60 mg is a high-quality Denosumab injection in ready-to-use pre-filled syringes (PFS), a biosimilar equivalent of the internationally recognized RANKL-targeting monoclonal antibody marketed under the brand names Prolia® and Xgeva®. Manufactured in WHO-GMP certified facilities, DENUB is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs for bone-related disorders.

Denosumab is a fully human monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand), a key mediator of osteoclast formation, function, and survival. By blocking RANKL, DENUB effectively reduces bone resorption and strengthens bone density, making it an essential therapy for conditions such as osteoporosis, bone loss associated with hormone ablation therapy in cancer patients, and prevention of skeletal-related events in patients with bone metastases.

DENUB 60 mg Injection Twin Pack (2 PFS) is primarily indicated for the treatment of osteoporosis in postmenopausal women, treatment-induced bone loss, and management of skeletal complications in patients with solid tumors or multiple myeloma.

DENUB 60 mg Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The twin pack pre-filled syringes are supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, oncology centers, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Denosta 60mg/mL Denosumab Injection
Composition: Denosumab 60mg / 1mL Solution for Injection
International Trade Name: Prolia®

Denosta 60 is a high-quality Denosumab 60mg/mL Injection, a biosimilar equivalent of the internationally recognized RANKL-targeted monoclonal antibody marketed under the brand name Prolia®. Manufactured in WHO-GMP certified facilities, Denosta Injection is supplied by trusted pharmaceutical exporters from India to support advanced global osteoporosis and bone health treatment programs, particularly in patients at risk of fractures.

Denosumab is a fully human monoclonal antibody that binds to and inhibits RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand), preventing osteoclast formation, function, and survival, thereby reducing bone resorption and increasing bone mass and strength. Denosta 60mg/mL Injection is primarily indicated for the treatment of osteoporosis in postmenopausal women, men at increased risk of fractures, and patients receiving certain cancer therapies that compromise bone health.

Denosta 60 Denosumab Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Rozel Denosumab Solution for Injection PFS 60 mg/ml
Composition: Denosumab 60 mg/ml Injection
International Trade Name: Prolia® / Xgeva®

Rozel 60 is a high-quality Denosumab injection in a ready-to-use pre-filled syringe (PFS), a biosimilar equivalent of the internationally recognized RANKL-targeting monoclonal antibody marketed under the brand names Prolia® and Xgeva®. Manufactured in WHO-GMP certified facilities, Rozel 60 is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs for bone-related disorders.

Denosumab is a fully human monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand), a key mediator of osteoclast formation, function, and survival. By blocking RANKL, Rozel 60 effectively reduces bone resorption and strengthens bone density, making it an essential therapy for conditions such as osteoporosis, bone loss associated with hormone ablation therapy in cancer patients, and prevention of skeletal-related events in patients with bone metastases.

Rozel Denosumab Solution for Injection PFS 60 mg/ml is primarily indicated for the treatment of osteoporosis in postmenopausal women, treatment-induced bone loss, and management of skeletal complications in patients with solid tumors or multiple myeloma.

Rozel 60 Denosumab PFS is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The pre-filled syringe is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, oncology centers, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Denosurel 120mg Denosumab Injection
Composition: Denosumab 120mg / 1mL Solution for Injection
International Trade Name: Prolia®

Denosurel 120 is a high-quality Denosumab 120mg Injection, a biosimilar equivalent of the internationally recognized RANKL-targeted monoclonal antibody marketed under the brand name Prolia®. Manufactured in WHO-GMP certified facilities, Denosurel Injection is supplied by trusted pharmaceutical exporters from India to support advanced global osteoporosis and bone health treatment programs, particularly in patients at high risk of fractures.

Denosumab is a fully human monoclonal antibody that binds to and inhibits RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand), preventing osteoclast formation, function, and survival, thereby reducing bone resorption and increasing bone mass and strength. Denosurel 120mg Injection is primarily indicated for the treatment of osteoporosis in postmenopausal women, men at increased risk of fractures, and patients receiving certain cancer therapies that compromise bone health.

Denosurel 120 Denosumab Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Odensomab Denosumab Injection 60 mg/ml
Composition: Denosumab 60 mg/ml Injection
International Trade Name: Prolia® / Xgeva®

Odensomab 60 is a high-quality Denosumab injection, a biosimilar equivalent of the internationally recognized RANKL-targeting monoclonal antibody marketed under the brand names Prolia® and Xgeva®. Manufactured in WHO-GMP certified facilities, Odensomab is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs for bone-related disorders.

Denosumab is a fully human monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand), a key mediator of osteoclast formation, function, and survival. By blocking RANKL, Odensomab effectively reduces bone resorption and strengthens bone density, making it an essential therapy for conditions such as osteoporosis, bone loss associated with hormone ablation therapy in cancer patients, and prevention of skeletal-related events in patients with bone metastases.

Odensomab Denosumab Injection 60 mg/ml is primarily indicated for the treatment of osteoporosis in postmenopausal women, treatment-induced bone loss, and management of skeletal complications in patients with solid tumors or multiple myeloma.

Odensomab 60 Denosumab Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, oncology centers, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Denoci-OP 60mg/mL Denosumab Injection
Composition: Denosumab 60mg / 1mL Solution for Injection
International Trade Name: Prolia®

Denoci-OP 60 is a high-quality Denosumab 60mg/mL Injection, a biosimilar equivalent of the internationally recognized RANKL-targeted monoclonal antibody marketed under the brand name Prolia®. Manufactured in WHO-GMP certified facilities, Denoci-OP Injection is supplied by trusted pharmaceutical exporters from India to support advanced global osteoporosis and bone health treatment programs, particularly in patients at risk of fractures.

Denosumab is a fully human monoclonal antibody that binds to and inhibits RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand), preventing osteoclast formation, function, and survival, thereby reducing bone resorption and increasing bone mass and strength. Denoci-OP 60mg/mL Injection is primarily indicated for the treatment of osteoporosis in postmenopausal women, men at increased risk of fractures, and patients receiving certain cancer therapies that compromise bone health.

Denoci-OP 60 Denosumab Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Denoci 120mg Denosumab Injection
Composition: Denosumab 120mg / 1mL Solution for Injection
International Trade Name: Prolia®

Denoci 120 is a high-quality Denosumab 120mg Injection, a biosimilar equivalent of the internationally recognized RANKL-targeted monoclonal antibody marketed under the brand name Prolia®. Manufactured in WHO-GMP certified facilities, Denoci Injection is supplied by trusted pharmaceutical exporters from India to support advanced global osteoporosis and bone health treatment programs, particularly in patients at high risk of fractures.

Denosumab is a fully human monoclonal antibody that binds to and inhibits RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand), preventing osteoclast formation, function, and survival, thereby reducing bone resorption and increasing bone mass and strength. Denoci 120mg Injection is primarily indicated for the treatment of osteoporosis in postmenopausal women, men at increased risk of fractures, and patients receiving certain cancer therapies that compromise bone health.

Denoci 120 Denosumab Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for tertiary care hospitals, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

DRONYRA Zoledronic Acid Injection IP 4 mg
Composition: Zoledronic Acid 4 mg/5 ml Injection
International Trade Name: Zometa® / Reclast®

DRONYRA 4 mg is a high-quality Zoledronic Acid injection, a bisphosphonate equivalent of the internationally recognized products Zometa® and Reclast®. Manufactured in WHO-GMP certified facilities, DRONYRA is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs for bone-related disorders and oncology care.

Zoledronic Acid is a potent bisphosphonate that inhibits osteoclast-mediated bone resorption, improving bone mineral density and reducing the risk of skeletal-related events. DRONYRA is used in the management of conditions such as osteoporosis, Paget’s disease of bone, and prevention of skeletal complications in patients with bone metastases from solid tumors.

DRONYRA Zoledronic Acid Injection 4 mg is primarily indicated for the treatment and prevention of osteoporosis in postmenopausal women, management of hypercalcemia of malignancy, and prevention of skeletal-related complications in patients with metastatic bone disease.

DRONYRA 4 mg Injection is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, oncology centers, osteoporosis clinics, government health programs, and international pharmaceutical distributors.

Denoclast 60mg/ml Pre-filled Syringe
Composition: Denosumab 60mg/ml Injection
International Trade Name: Prolia® / Xgeva®

Denoclast 60mg/ml is a high-quality Denosumab injection in a ready-to-use pre-filled syringe, a biosimilar equivalent of the internationally recognized RANKL-targeting monoclonal antibody marketed under the brand names Prolia® and Xgeva®. Manufactured in WHO-GMP certified facilities, Denoclast is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs for bone-related disorders.

Denosumab is a fully human monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand), a key mediator of osteoclast formation, function, and survival. By blocking RANKL, Denoclast effectively reduces bone resorption and strengthens bone density, making it an essential therapy for conditions such as osteoporosis, bone loss associated with hormone ablation therapy in cancer patients, and prevention of skeletal-related events in patients with bone metastases.

Denoclast 60mg/ml Pre-filled Syringe is primarily indicated for the treatment of osteoporosis in postmenopausal women, treatment-induced bone loss, and management of skeletal complications in patients with solid tumors or multiple myeloma.

Denoclast 60mg/ml Pre-filled Syringe is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The pre-filled syringe is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, oncology centers, osteoporosis clinics, government health programs, and international pharmaceutical distributors.